Basilea Pharmaceutica AG

As of June 30, 2026, Basilea Pharmaceutica AG carries a market capitalization of 660.91M, placing it among publicly traded companies globally. Its enterprise value stands at 571.30M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Basilea Pharmaceutica AG's next confirmed earnings release is scheduled for February 16, 2027.

As of June 30, 2026, Basilea Pharmaceutica AG has 12.38M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Basilea Pharmaceutica AG maintains a current ratio of 6.60, meaning it holds 6.6x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, Basilea Pharmaceutica AG's stock has gained approximately 42.74% over the past 52 weeks. The 50-day moving average sits at 65.68, while the 200-day moving average is 56.43.

As of June 30, 2026, Basilea Pharmaceutica AG holds 173.05M in cash and equivalents against 83.44M in total debt, resulting in a net debt position of -102.41M. Total book value stands at 162.35M, with working capital of 232.29M providing operational flexibility.

Basilea Pharmaceutica AG's most recent stock split took place on March 13, 2007 with a 103:104 split ratio.